Pulmonary embolism landmark trials: Difference between revisions

Jump to navigation Jump to search
Line 36: Line 36:


===Study assessing the efficacy of Thrombolysis===   
===Study assessing the efficacy of Thrombolysis===   
1. '''MAPPET''' (Management Strategy and Prognosis of Pulmonary Embolism Registry) (1997).
1. '''MAPPET''' (Management Strategy and Prognosis of Pulmonary Embolism Registry) (1997).<ref name="pmid9264496">{{cite journal| author=Konstantinides S, Geibel A, Olschewski M, Heinrich F, Grosser K, Rauber K et al.| title=Association between thrombolytic treatment and the prognosis of hemodynamically stable patients with major pulmonary embolism: results of a multicenter registry. | journal=Circulation | year= 1997 | volume= 96 | issue= 3 | pages= 882-8 | pmid=9264496 | doi= | pmc= | url= }} </ref>


===Study assessing the factors causing death===  
===Study assessing the factors causing death===  

Revision as of 22:01, 21 January 2012

Pulmonary Embolism Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Pulmonary Embolism from other Diseases

Epidemiology and Demographics

Risk Factors

Triggers

Natural History, Complications and Prognosis

Diagnosis

Diagnostic criteria

Assessment of Clinical Probability and Risk Scores

Pulmonary Embolism Assessment of Probability of Subsequent VTE and Risk Scores

History and Symptoms

Physical Examination

Laboratory Findings

Arterial Blood Gas Analysis

D-dimer

Biomarkers

Electrocardiogram

Chest X Ray

Ventilation/Perfusion Scan

Echocardiography

Compression Ultrasonography

CT

MRI

Treatment

Treatment approach

Medical Therapy

IVC Filter

Pulmonary Embolectomy

Pulmonary Thromboendarterectomy

Discharge Care and Long Term Treatment

Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Follow-Up

Support group

Special Scenario

Pregnancy

Cancer

Trials

Landmark Trials

Case Studies

Case #1

Pulmonary embolism landmark trials On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Pulmonary embolism landmark trials

CDC on Pulmonary embolism landmark trials

Pulmonary embolism landmark trials in the news

Blogs on Pulmonary embolism landmark trials

Directions to Hospitals Treating Pulmonary embolism landmark trials

Risk calculators and risk factors for Pulmonary embolism landmark trials

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor-In-Chief: Ujjwal Rastogi, MBBS [2]

Landmark clinical Trials & Studies

Trials assessing the diagnosis

1. PIOPED (Prospective Investigation in Pulmonary Embolism Diagnosis) (1989).[1]

(ClinicalTrials.gov number, NCT00000566).

  • Purpose : To evaluate the sensitivity and specificity of two major, widely used technologies, radionuclear imaging (ventilation-perfusion scanning) and pulmonary angiography, for the diagnosis of pulmonary embolism.
  • Study Type: Interventional
  • Study Design: Primary Purpose: Diagnostic

2. PIOPED II (Prospective Investigation in Pulmonary Embolism Diagnosis II) (2002).[2]

(ClinicalTrials.gov number, NCT00007085).

  • Purpose : It was designed to assess the efficacy of the spiral computed tomographic pulmonary angiogram in patients suspected of having acute pulmonary embolism (PE).
  • Study Type: Interventional
  • Study Design: Primary Purpose: Diagnostic
  • Comparison with PIOPED: In contrast to the original PIOPED study, which used contrast pulmonary angiography as the primary reference test for PE, PIOPED II used composite reference test for venous thromboembolism that was based on the ventilation/perfusion lung scan, venous compression ultrasound of the lower extremities, digital subtraction pulmonary angiography, and contrast venography in various combinations to establish the PE status of the patient. New criteria for ventilation/perfusion lung scan diagnosis were developed for PIOPED II.

3. PIOPED III (Prospective Investigation of Pulmonary Embolism Diagnosis III) (2010). [3]

(ClinicalTrials.gov number, NCT00241826).

  • Purpose :The purpose of this study is to determine the diagnostic accuracy of gadolinium-enhanced magnetic resonance angiography (Gd-MRA) of the pulmonary arteries in combination with magnetic resonance venography (MRV) of the veins of the thighs in patients with clinically suspected acute pulmonary embolism (PE).
  • Study Type: Observational
  • Study Design: Observational Model:Cohort, Time Perspective:Prospective.

Trials assessing the efficacy of LMWH in reducing mortality in acutely ill patients

1. LIFENOX (Study to Evaluate the Mortality Reduction of Enoxaparin in Hospitalized Acutely Ill Medical Receiving Enoxaparin) (2011).[4]

(ClinicalTrials.gov number, NCT00622648).

  • Study Type: Interventional
  • Study Design: Primary Purpose: Treatment, Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator).
  • Conclusion: Enoxaparin plus elastic stockings with graduated compression, failed to show any reduction in the rate of death from any cause among hospitalized, acutely ill medical patients, when compared to elastic stockings with graduated compression alone.

Study assessing the efficacy of Thrombolysis

1. MAPPET (Management Strategy and Prognosis of Pulmonary Embolism Registry) (1997).[5]

Study assessing the factors causing death

1. ICOPER (International Cooperative Pulmonary Embolism Registry) (1999).[6]

References

  1. "Value of the ventilation/perfusion scan in acute pulmonary embolism. Results of the prospective investigation of pulmonary embolism diagnosis (PIOPED). The PIOPED Investigators". JAMA. 263 (20): 2753–9. 1990. PMID 2332918. |access-date= requires |url= (help)
  2. Gottschalk A, Stein PD, Goodman LR, Sostman HD (2002). "Overview of Prospective Investigation of Pulmonary Embolism Diagnosis II". Semin Nucl Med. 32 (3): 173–82. doi:10.1053/snuc.2002.124177. PMID 12105798. Retrieved 2012-01-10. Unknown parameter |month= ignored (help)
  3. Stein PD, Chenevert TL, Fowler SE, Goodman LR, Gottschalk A, Hales CA, Hull RD, Jablonski KA, Leeper KV, Naidich DP, Sak DJ, Sostman HD, Tapson VF, Weg JG, Woodard PK (2010). "Gadolinium-enhanced magnetic resonance angiography for pulmonary embolism: a multicenter prospective study (PIOPED III)". Ann. Intern. Med. 152 (7): 434–43, W142–3. doi:10.1059/0003-4819-152-7-201004060-00008. PMC 3138428. PMID 20368649. Unknown parameter |month= ignored (help); |access-date= requires |url= (help)
  4. Kakkar AK, Cimminiello C, Goldhaber SZ, Parakh R, Wang C, Bergmann JF (2011). "Low-molecular-weight heparin and mortality in acutely ill medical patients". N. Engl. J. Med. 365 (26): 2463–72. doi:10.1056/NEJMoa1111288. PMID 22204723. Retrieved 2012-01-13. Unknown parameter |month= ignored (help)
  5. Konstantinides S, Geibel A, Olschewski M, Heinrich F, Grosser K, Rauber K; et al. (1997). "Association between thrombolytic treatment and the prognosis of hemodynamically stable patients with major pulmonary embolism: results of a multicenter registry". Circulation. 96 (3): 882–8. PMID 9264496.
  6. Goldhaber SZ, Visani L, De Rosa M (1999). "Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER)". Lancet. 353 (9162): 1386–9. PMID 10227218. Retrieved 2012-01-13. Unknown parameter |month= ignored (help)

Template:WH Template:WS